Τόμος 28 (2010) – Τεύχος 2 – Άρθρο 3 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 28 (2010) – Issue 2 – Article 3 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Παναγιώτα Κυριάκου¹, Χαραλαμπία Κυριάκου²

¹Επιμελήτρια, Β΄ Παθολογική Κλινική, Αριστοτέλειο Πανεπιστήμιο, Θεσσαλονίκη, Ελλάς
²Αιματολόγος, MD, PhD, Northwick Park NHS Consultant, Royal Free NCLs Medical School

P. Kyriakou¹, Ch. Kyriakou²

¹2^nd Dept. of Cardioliology, Ippokrateion Clinic, Aristotle University, Thessaloniki, Hellas
²Consultant Haematologist, North West London NHS Trust, Royal Free and UCL Medical School, London, UK

2. Martins E., Silva-Cardoso J., Bicho M., et al.: Portuguese study of familial dilated cardiomyopathy: the FATIMA study. Rev. Port. Cardiol. 27: 1029-1042 (2008)

3. Priori, S.G., Napolitano C., Humphries S., et al.: Genetics of Cardiovascular Diseases: Dilated cardiomyopathy. In: The ESC Textbook of Cardiovascular Medicine (J. Camm, T. Lüscher, P. Serruys) Chapter 7, pp 193-196, 2006

4. Song K., Dube M.P., Lim J., et al.: Lamin A/C mutations associated with familial and sporadic cases of dilated cardiomyopathy in Koreans. Exp. Mol. Med. 39: 114-120 (2007)

5. Murphy R.T., Starling R.C.: The genetics of cardiomyopathy- Implications for clinical practice. Καρδιακή Ανεπάρκεια 2: 21-34 (2005)

6. Κίτσιος Γ., Χατζηγεωργίου Γ., Τρυποσκιάδης Φ.: Γενετική των μιτοχονδριακών μυοκαρδιοπαθειών. Καρδιακή Ανεπάρκεια 2: 131-145 (2005)

7. Posch M.G., Posch M.J., Geier C., et al.: A missense variant in desmoglein-2 predisposes to dilated cardiomyopathy. Mol. Genet. Metab. 95: 74-80 (2008)

8. Finsterer J., Stoellberger C.: The heart in human dystrophinopathies. Cardiology 99: 1-19 (2003)

9. Muntoni S., Torelli S., Ferlini A.: Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2: 731-740 (2003)

10. Tsubata S., Bowels K.R., Vatta M., et al.: Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J. Clin. Invest. 106: 655-62 (2000)

11. Ischida F., Tsubata S., Bowles K.R., et al. Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome. Circulation 103: 1256-1263 (2001)

12. Dalakas M.C., Park K.Y., Semino-Mora C., et al.: Desmin myopathy a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. N. Engl. J. Med. 343: 770-780 (2000)

13. Fatkin D., MacCrae C.A., Sasaki T., et al.: Missense mutations in the rod domain of the Lamin a/c gene as causes of dilated cardiomyopathy and conduction system disease. N. Engl. J. Med. 341: 1715-1724 (1999)

14. Parks S.B., Kushner J.D., Nauman D., et al.: Lamin A/C mutation analysis in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy. Am. Heart J. 156: 161-169 (2008)

15. Pasotti M., Klersy C., Pilotto A., et al.: Long-term outcome and risk stratification in dilated cardiolaminopathies. J. Am Coll. Cardiol. 52: 1250-1260 (2008)

16. Kamisago M., Sharma S.D., DePalma S.R., et al.: Mutations in scarcomere protein genes as a cause of dilated cardiomyopathy. N. Engl. J. Med. 343: 1688-1696 (2000)

17. Murphy R.T., Mogensen J., Shaw A.L., et al.: Troponin I is a novel recessive disease gene in familial Dilated Cardiomyopathy. Lancet 363: 371-372 (2004)

18. Mogensen J., Murphy R.T., Bahl A., et al.: Severe disease expression of Cardiac Troponin C and T mutations in patients with Idiopathic Dilated Cardiomyopathy. J. Am. Coll. Cardiol. 44: 2033-2040 (2004)

19. Olson T.M., Michels V.V., Thibodeau S.N., et al.: Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 280: 750-752 (1998)

20. Lim C.C., Yang H., Yang M., et al.: A novel mutant cardiac troponin C disrupts molecular motions critical for calcium binding affinity and cardiomyocyte contractility. Biophys. J. 94: 3577-3589 (2008)

21. Schmitt J.P., Kamisago M., Asahi M., et al.: Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299: 1410-1413 (2003)

22. Haghighi K., Kolokathis F., Pater L., et al.: Human phospholamban null results in lethal dilated cardiomyopathy reveal-ing a critical difference between mouse and human. J. Clin. Invest. 111: 869-876 (2003)

23. McNair W.P., Ku L., Taylor M.R., et al.: SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia. Circulation 110: 2163-2167 (2004)

24. Shi R., Zhang Y., Yang C., et al: The cardiac sodium channel mutation delQKP1507-1509 is associated with the expanding phenotypic spectrum of LQT3, conduction disorder, dilated cardiomyopathy, and high incidence of youth sudden death. Europace 10: 1329-1335 (2008)

25. Murphy R.T., Thaman R., Gimeno Blanes J., et al.: Natural History and Familial Characteristics of Isolated Left Ventricular Non-Compaction. Eur. Heart J. 26: 187-192 (2005)

26. Rigopoulos A., Rizos I.K., Aggeli C., et al.: Isolated left ventricular noncompaction: an unclassified cardiomyopathy with severe prognosis in adults. Cardiology 98: 25-32 (2002)

27. Steffel J., Kobza R., Namdar M., et al.: Electrophysiological findings in patients with isolated left ventricular non-compaction. Europace 11: 1193-1200 (2009)

28. Vatta M., Mohapatra B., Jimenez S., et al.: Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non compaction. J. Am. Coll. Cardiol. 42: 2014-2027 (2003)

29. Ruppert V., Nolte D., Aschenbrenner T., et al.: Novelpoint mutations in the mitochondrial DNA detected in patients with dilate cardiomyopathy by screening the whole mitochondrial genome. Biochem. Biophys. Res. Commun. 318: 535-543 (2004)

30. Brega A., Narula J., Arbustini E., et al.: Functional, structural and genetic mitochondrial abnormalities in myocardial diseases. J. Nucl. Cardiol. 8: 89-97 (2001)

31. Kyriakidis T., Drousiotou A., Panasopoulou A., et al.: A comparative morphological study in 33 cases of respiratory chain encephalomyopathies. Acta Myol. 22: 48-51 (2003)

32. Richardson P., McKenna W., Bristow M., et al.: Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93: 841-842 (1996)

33. Antozzi C., Zeviani M.: Cardiomyopathies in disorders of oxidative metabolism. Cardiovasc. Res. 35: 184-199 (1997)

34. Papadimitriou A., Hadjigeorgiou G.M., Divari R., et al.: The influence of Coenzyme Q10 on total serum calcium concentration in two patients with Kearns-Sayre Syndrome and hypoparathyroidism. Neuromuscul. Disord. 6: 49-53 (1996)

35. Muller-Hocker J., Jacob U., Seibel P.: The common 4877 base pair deletion of mitochondrial DNA preferentially accumulates in the cardiac conduction system of patients with Kearns-Sayre syndrome. Mod. Pathol. 11: 295-301 (1998)

36. Zeviani M., Di Donato S.: Mitochondrial disorders. Brain 127: 2153-2172 (2004)

37. Takei Y., Ikeda S., Yanagisawa N., et al.: Multiple mitochondrial DNA deletions in patients with mitochondrial myopathy and cardiomyopathy but no ophthalmoplegia. Muscle Nerve 18: 1321-1325 (1995)

38. Suomalainen A., Paetau A., Leinonen H., et al.: Inherited idiopathic dilated cardiomyopathy with multiple deletions of mitochondrial DNA. Lancet 340(8831): 1319-1320 (1992)

39. Taniike M., Fukushima H., Yanagihara I., et al.: Mitochondrial tRNA (Ile) mutation in fatal cardiomyopathy. Biochem. Biophys. Res. Commun. 186: 47-53 (1992)

40. Valnot I., von Kleist-Retzow J.C., Barrientos A., et al.: A mutation in the human heme A:farnesyltransferase gene (COX10) causes cytochrome c oxidase deficiency. Hum. Mol. Genet. 9: 1245-1249 (2000)

41. Zhang D., Ezekiel U.R., Chang S.W., Zassenhaus H.P.: Gene expression profile in dilated cardiomyopathy caused by elevated frequencies of mitochondrial DNA mutations in the mouse heart. Cardiovasc. Pathol. 14: 61-69 (2005)

42. Smith P.M., Ross G.F., Taylor R.W., et al.: Strategies for treating disorders of the mitochondrial genome. Biochim. Biophys. Acta 1659: 232-239 (2004)